(Z) -LFM-A13

CAT: 0804-HY-18009-01Size: 5 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-18009-01Size:5 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.

CAS Number

244240-24-2

UNSPSC

12352005

Hazard Statement

H302+H312+H332

Target

Btk; JAK; Polo-like Kinase (PLK)

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/z-lfm-a13.html

Purity

99.80

Solubility

DMSO : ≥ 42 mg/mL

Smiles

BrC1=C(NC(/C(C#N)=C(C)\O)=O)C=C(Br)C=C1

Molecular Formula

C11H8Br2N2O2

Molecular Weight

360.01

Precautions

H302+H312+H332

References & Citations

[1]Mahajan S, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N- (2, 5-dibromophenyl) propenamide]. J Biol Chem. 1999 Apr 2;274 (14) :9587-99.|[2]van den Akker E, et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem. 2004 May;385 (5) :409-13.|[3]"Sahin K, et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Invest New Drugs. 2017 Nov 15. "|[4]Uckun FM, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK) . Bioorg Med Chem. 2007 Jan 15;15 (2) :800-14. Epub 2006 Oct 26.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

PLK1; PLK3

Related Products

Catalog	Name
HY-110002-01	LFM-A13
HY-N8295	Leucomycin A13
HY-163436	F44-A13
HY-159706-01	S9-A13
HY-P11246	A13:B7-24-GG
HY-P7514-01	Annexin A13/ANXA13, Human
HY-165956	4 (Z), 7 (Z), 10 (Z), 13 (Z), 16 (Z), 19 (Z) -Docosahexaenol
HY-165748	7 (Z), 10 (Z), 13 (Z), 16 (Z), 19 (Z) -Docosapentaenol
HY-166213	Ethyl 6 (Z),9 (Z),12 (Z),15 (Z),18 (Z),21 (Z) -tetracosahexaenoate
HY-165962	4 (Z),7 (Z),10 (Z),13 (Z),16 (Z),19 (Z) -Docosahexaenyl acetate

Alternative Products

Catalog	Name
B5952-10	LFM-A13
MBS808161-01	LFM A13

(Z) -LFM-A13

Related Products

Alternative Products

Popular Products